Objectives: This analysis aimed to evaluate the cost-effectiveness of pembrolizumab
compared with docetaxel in patients with previously treated advanced non-squamous cell …

Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with
standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) …

Objectives Our objectives were to evaluate the cost effectiveness of pembrolizumab
compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment …

Aims: To describe cost-effectiveness of pembrolizumab plus platinum and pemetrexed
chemotherapy in metastatic, non-squamous, NSCLC patients in the US. Materials and …

Objective The purpose of this study was to estimate the cost-effectiveness analysis of
pembrolizumab versus chemotherapy as first-line treatment in locally advance or metastatic …

Background Pembrolizumab, a monoclonal antibody against programmed death ligand 1
(PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non …

Introduction Pembrolizumab monotherapy or in combination with chemotherapy are two new
treatment options for patients with metastatic non-squamous non-small cell lung cancer …

Purpose: Pembrolizumab was recently approved in several countries as a first-line treatment
for patients with PD-L1 positive, non-small cell lung cancer (NSCLC). However, it is …

Background Pharmacoeconomic information for pembrolizumab as a second-line lung
cancer treatment is insufficient in China, so we aimed to assess its cost-effectiveness versus …

Objectives This study aimed to assess the cost-effectiveness of pembrolizumab
monotherapy compared with chemotherapy as first-line treatment in patients with locally …